2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2281

Treatment Choices and Response Rates of SAPHO Syndrome: Single Center Case Series
Abstract Number: 2282

Measurement of the Pro-Coagulant Activity of Microparticles in Patients with Inflammatory Rheumatic Diseases: Prospective Study
Abstract Number: 2283

Incidental Steroid Use May Worsen Outcomes in Patients with Heparin Induced Thrombocytopenia in the ICU Setting
Abstract Number: 2284

Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated on an Open-Label Extension of Trial JBT101-DM-001
Abstract Number: 2285

Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Abstract Number: 2286

Myositis and Fasciitis By Magnetic Resonance Imaging in Recent-Onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy
Abstract Number: 2287

Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Abstract Number: 2288

Preexisting Anti-Acetylcholine Receptor Autoantibodies and B Cell Lymphopenia Are Associated with the Development of Myositis in Thymoma Patients Treated with Avelumab, an Immune Checkpoint Inhibitor Targeting Programmed Death-Ligand 1
Abstract Number: 2289

Granulomatous Myositis: Heterogeneity and Response to Treatment
Abstract Number: 2290

Long Term Follow-up Results of Myositis Patients Treated with H. P. Acthar Gel
Abstract Number: 2291

Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers
Abstract Number: 2292

The Predictive Risk Factors for Opportunistic Infection during Immunosuppressive Therapy for Polymyositis/Dermatomyositis
Abstract Number: 2293

Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort
Abstract Number: 2294

Improving EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies
Abstract Number: 2295

Classification of Idiopathic Inflammatory Myopathies: Assessment of 123 Patients According to 2017 Acr/EULAR Criteria Followed up By a Single Center from Turkey

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].